Elsevier recognizes Alzheimer’s – Brain Awareness Month with new book, "A Roadmap for Curing Cancer, Alzheimer’s, and Cardiovascular Disease"

One of six new neuroscience titles, groundbreaking book analyzes the failures in curing Alzheimer’s, cancer and cardiovascular disease and proposes solutions

Cambridge, MA, June 6, 2017

Elsevier, the information analytics company specializing in science and health, today announced A Roadmap for Curing Cancer, Alzheimer's, and Cardiovascular Disease by Paul J. Marangos. One of six new neuroscience books recognizing June as Alzheimer’s – Brain Awareness Month, this is the first book to address the reasons that cures for these diseases have failed, and to provide a detailed roadmap for life science researchers to conquer terminal illnesses.

Dementia, cancer and cardiovascular disease are responsible for almost two million deaths each year in the United States alone and represent the largest immediate threat to humanity. A Roadmap for Curing Cancer, Alzheimer's, and Cardiovascular Disease defines deficiencies in academic life science research, including conflicting incentives and QA/QC issues, and offers recommendations on how to eliminate them. It provides a rationale for FDA reform, and details how a reformed NIH can partner with regulators and industry to create a NASA-type effort to speed cures of terminal diseases.

Preview the book’s call to action and proposed reforms in this article by Dr. Marangos.

Dr. Marangos is the author of more than 250 peer-reviewed research papers on neurobiology, and four books, three published by Elsevier’s Academic Press. He is a founding editor of “The Journal of Molecular Neuroscience” and the inventor on 14 issued patents. Dr. Marangos spent 13 years at the National Institute of Mental Health and was adjunct professor of neurochemistry at GW School of Medicine & Health Sciences during that time. He is a co-founder of five biotechnology firms with 20+ years of experience as CEO of both public and private life science companies. Dr. Marangos has had extensive experience in all aspects of the pharmaceutical and biotechnology industries, from bench to product. Coupled with his academic experience, this has provided him with a global perspective on the entire medical R&D enterprise, in particular its faults, as well as possible remedies to speed the quest for cures.

The six new neuroscience titles are:

In order to meet content needs in neuroscience, Elsevier uses proprietary tools to identify the gaps in coverage of the topics. Editorial teams strategically fill those gaps with content written by key influencers in the field, giving students, faculty and researchers the content they need to answer challenging questions and improve outcomes. These new books, which will educate the next generation of neuroscientists, and provide critical foundational content for information professionals, are key examples of how Elsevier is enabling science to drive innovation.

---

Note for editors
Credentialed media can request e-book review copies by email, please contact sciencereviewcopies@elsevier.com

About Elsevier
Elsevier is a global information analytics company that helps institutions and professionals progress science, advance healthcare and improve performance for the benefit of humanity. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, more than 35,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX Group, a global provider of information and analytics for professionals and business customers across industries. www.elsevier.com

Media contact
Pam Foote
Publicity Contact, Science & Technology Books, Elsevier
footep@reedelsevier.com
+1 978 837 8182